New Chemical Entity

New Chemical Entity Definition & Introduction

New Chemical Entity: Definition & Introduction

New Drug Products (NDP) is defined as any pharmaceutical products that have not been previously registered in accordance with the provisions of the CDCR 1984.

An NDP may be classified according to the following categories:

(a) New NCE (single/ combination products with an active substance never registered by DCA)

Defined as an active moiety/ radiopharmaceutical substance that has not been registered in any pharmaceutical product.

An active moiety is defined as the molecule or ion, excluding those appended portions of the molecule that cause the drug to be an        ester, salt (including a salt with hydrogen or coordination bonds) or other noncovalent derivative (such as complex, chelate, or clathrate) of the molecule, responsible for the physiological or pharmacological action of the drug substance.

A radiopharmaceutical substance is defined as a radionucleotide, ligand or the coupling mechanism to link the molecule and the radionucleotide that has not been registered in any pharmaceutical product.

(b) Hybrid NCE (single/ combination products with registered active moieties)

All other products registrable at New Drug Section which do not fall under (a).

Examples of Hybrid NCE (combination) products:

i. Combination of registered chemical entities

ii. Combination of registered chemical entity(s) in new chemical form(s)

iii. Combination of registered chemical entity(s) in new chemical form(s) and registered chemical entity(s)

Examples of Hybrid NCE (single) products:

i. Registered chemical entity in a new chemical form

ii. Registered chemical entity in a new dosage form

iii. Registered chemical entity in a new dosage strength with a change in dosing/ posology

iv. registered chemical entity for use by a new route of administration

v. Registered chemical entity for new indication(s), dosage recommendation(s) and/or patient population(s)

vi. A generic product for which its innovator has never been registered by DCA

NOTE:

For a generic product in which the reference innovator product has never been registered in Malaysia, specific requirements for Parts III and IV:

i) Nonclinical Overview, Nonclinical Summary & List of Key Literature references, by referring to studies by the innovator product

ii) Clinical Overview, Clinical Summary & List of Key literature References, by referring to studies by the innovator product

iii) Bioequivalence study report(s)

iv) other pivotal study reports, if applicable

v) Risk Management Plan (RMP)

vi) Consultation with local clinical specialists 





Recent Updates, Directives & Circulars


  • Recent Updates for Guidelines, Circulars, Directives, FAQ & Announcements for New Chemical Entity
  • Directives & Circulars Related to New Chemical Entity

Product Registration Process

Step I : Preparation

Product classification, Token Configuration, Payment Mode, Patent and Data Exclusivity status and Ensure key documents availability.

Pre-submission of Application (Preparation)

Step I : Preparation

Step 2 : Submission

Key-in, upload documents and submit your application (Part I, Part II, Part III & Part IV)

Product Validation, Part I, Part II, Part III & Part IV

Step 2 : Submission

Step 3 : Regulatory Outcome

Evaluation of Application & Drug Control Authority (DCA) decision.

Evaluation of Application & Drug Control Authority (DCA) decision.

Step 3 : Regulatory Outcome

Step 4 : Post-registration Process

Maintenance of Registration, Withdrawal of Product Registration, Amendment to the particulars of the product, Post marketing activities

Maintenance of Registration, Withdrawal of Product Registration, Amendment to the particulars of the product, Post marketing activities

Step 4 : Post-registration Process

National Pharmaceutical Regulatory Agency (NPRA)
Lot 36, Jalan Universiti, 46200 Petaling Jaya, Selangor, Malaysia.
  • Email: npra@npra.gov.my
  • Phone: +603-7883 5400
  • Fax: +603-7956 2924, +603-7956 7075

DISCLAIMER

The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Mobile Web :

Site Last Modified

  • Last Modified: Wednesday 20 November 2019, 11:12:25.
© Copyright 2019 . All Rights Reserved National Pharmaceutical Regulatory Agency NPRA

Main Menu English

Choose Your Language